JP2012519005A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012519005A5 JP2012519005A5 JP2011552223A JP2011552223A JP2012519005A5 JP 2012519005 A5 JP2012519005 A5 JP 2012519005A5 JP 2011552223 A JP2011552223 A JP 2011552223A JP 2011552223 A JP2011552223 A JP 2011552223A JP 2012519005 A5 JP2012519005 A5 JP 2012519005A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- differentiation
- medium
- cell
- pluripotent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 653
- 230000004069 differentiation Effects 0.000 claims description 307
- 210000002242 embryoid body Anatomy 0.000 claims description 269
- 238000000034 method Methods 0.000 claims description 190
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 178
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 125
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 125
- 108010002386 Interleukin-3 Proteins 0.000 claims description 99
- 102100039064 Interleukin-3 Human genes 0.000 claims description 98
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 93
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 93
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 75
- 239000003112 inhibitor Substances 0.000 claims description 75
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 73
- 239000003102 growth factor Substances 0.000 claims description 70
- 239000011435 rock Substances 0.000 claims description 63
- 108090001005 Interleukin-6 Proteins 0.000 claims description 60
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims description 59
- 108010082117 matrigel Proteins 0.000 claims description 46
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 claims description 45
- 238000012258 culturing Methods 0.000 claims description 43
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 40
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 40
- 229910052760 oxygen Inorganic materials 0.000 claims description 39
- 210000002966 serum Anatomy 0.000 claims description 39
- -1 CD31 Proteins 0.000 claims description 37
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 claims description 37
- 102100039564 Leukosialin Human genes 0.000 claims description 37
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 35
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims description 32
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims description 32
- 239000002753 trypsin inhibitor Substances 0.000 claims description 31
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 30
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 30
- 229940122618 Trypsin inhibitor Drugs 0.000 claims description 29
- 101710162629 Trypsin inhibitor Proteins 0.000 claims description 29
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 29
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 27
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 27
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 27
- 239000001301 oxygen Substances 0.000 claims description 27
- 239000011159 matrix material Substances 0.000 claims description 25
- 102000004142 Trypsin Human genes 0.000 claims description 24
- 108090000631 Trypsin Proteins 0.000 claims description 24
- 239000012588 trypsin Substances 0.000 claims description 24
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 17
- 210000000066 myeloid cell Anatomy 0.000 claims description 16
- 210000004698 lymphocyte Anatomy 0.000 claims description 15
- 239000003446 ligand Substances 0.000 claims description 13
- 108010002586 Interleukin-7 Proteins 0.000 claims description 11
- 230000035755 proliferation Effects 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 108010002350 Interleukin-2 Proteins 0.000 claims description 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 210000003643 myeloid progenitor cell Anatomy 0.000 claims description 9
- 108010002335 Interleukin-9 Proteins 0.000 claims description 8
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 8
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 8
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims description 8
- 210000000822 natural killer cell Anatomy 0.000 claims description 8
- 108090000177 Interleukin-11 Proteins 0.000 claims description 7
- 210000000267 erythroid cell Anatomy 0.000 claims description 7
- 108010010803 Gelatin Proteins 0.000 claims description 6
- 108010085895 Laminin Proteins 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- 210000003924 normoblast Anatomy 0.000 claims description 6
- 108010031318 Vitronectin Proteins 0.000 claims description 5
- 102100035140 Vitronectin Human genes 0.000 claims description 5
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 5
- 102000003816 Interleukin-13 Human genes 0.000 claims description 4
- 108090000176 Interleukin-13 Proteins 0.000 claims description 4
- 108010039918 Polylysine Proteins 0.000 claims description 4
- 108060008245 Thrombospondin Proteins 0.000 claims description 4
- 102000002938 Thrombospondin Human genes 0.000 claims description 4
- 229920000656 polylysine Polymers 0.000 claims description 4
- 101710177504 Kit ligand Proteins 0.000 claims 4
- 108010092408 Eosinophil Peroxidase Proteins 0.000 claims 2
- 101710113649 Thyroid peroxidase Proteins 0.000 claims 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 102000000646 Interleukin-3 Human genes 0.000 claims 1
- 239000002609 medium Substances 0.000 description 281
- 229940076264 interleukin-3 Drugs 0.000 description 91
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 90
- 230000003394 haemopoietic effect Effects 0.000 description 66
- 102000004127 Cytokines Human genes 0.000 description 60
- 108090000695 Cytokines Proteins 0.000 description 60
- 102000036693 Thrombopoietin Human genes 0.000 description 59
- 108010041111 Thrombopoietin Proteins 0.000 description 59
- 239000007640 basal medium Substances 0.000 description 59
- 102000004889 Interleukin-6 Human genes 0.000 description 56
- 210000000130 stem cell Anatomy 0.000 description 56
- 210000002889 endothelial cell Anatomy 0.000 description 54
- 229940100601 interleukin-6 Drugs 0.000 description 54
- 239000001963 growth medium Substances 0.000 description 47
- 210000003593 megakaryocyte Anatomy 0.000 description 43
- 108700014844 flt3 ligand Proteins 0.000 description 36
- 230000012010 growth Effects 0.000 description 35
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 30
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 30
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 29
- 239000000203 mixture Substances 0.000 description 29
- 230000015572 biosynthetic process Effects 0.000 description 27
- 239000002243 precursor Substances 0.000 description 27
- 239000002253 acid Substances 0.000 description 26
- 244000068988 Glycine max Species 0.000 description 25
- 235000010469 Glycine max Nutrition 0.000 description 25
- 210000001671 embryonic stem cell Anatomy 0.000 description 25
- 210000002540 macrophage Anatomy 0.000 description 24
- 241000252212 Danio rerio Species 0.000 description 21
- 229940098773 bovine serum albumin Drugs 0.000 description 20
- 102000003951 Erythropoietin Human genes 0.000 description 19
- 108090000394 Erythropoietin Proteins 0.000 description 19
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 19
- 210000004443 dendritic cell Anatomy 0.000 description 19
- 210000003743 erythrocyte Anatomy 0.000 description 19
- 229940105423 erythropoietin Drugs 0.000 description 19
- 238000004519 manufacturing process Methods 0.000 description 19
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 19
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 18
- 210000003630 histaminocyte Anatomy 0.000 description 18
- 230000001965 increasing effect Effects 0.000 description 18
- 238000012423 maintenance Methods 0.000 description 18
- 238000005516 engineering process Methods 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 238000004113 cell culture Methods 0.000 description 16
- 230000024245 cell differentiation Effects 0.000 description 16
- 238000000684 flow cytometry Methods 0.000 description 16
- 210000003714 granulocyte Anatomy 0.000 description 16
- 239000011668 ascorbic acid Substances 0.000 description 15
- 229960005070 ascorbic acid Drugs 0.000 description 15
- 235000010323 ascorbic acid Nutrition 0.000 description 15
- 238000003556 assay Methods 0.000 description 15
- 230000010261 cell growth Effects 0.000 description 15
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 14
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 description 13
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 13
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 13
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 13
- 210000002950 fibroblast Anatomy 0.000 description 13
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 13
- 238000010899 nucleation Methods 0.000 description 13
- 210000001778 pluripotent stem cell Anatomy 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 12
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 12
- 229930182816 L-glutamine Natural products 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 230000000925 erythroid effect Effects 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 229920000609 methyl cellulose Polymers 0.000 description 12
- 239000001923 methylcellulose Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 12
- IYOZTVGMEWJPKR-IJLUTSLNSA-N Y-27632 Chemical compound C1C[C@@H]([C@H](N)C)CC[C@@H]1C(=O)NC1=CC=NC=C1 IYOZTVGMEWJPKR-IJLUTSLNSA-N 0.000 description 11
- 239000012091 fetal bovine serum Substances 0.000 description 11
- 239000012737 fresh medium Substances 0.000 description 11
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 10
- 102000029816 Collagenase Human genes 0.000 description 10
- 108060005980 Collagenase Proteins 0.000 description 10
- 102000003923 Protein Kinase C Human genes 0.000 description 10
- 108090000315 Protein Kinase C Proteins 0.000 description 10
- 238000013459 approach Methods 0.000 description 10
- 229960002424 collagenase Drugs 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 10
- 210000001616 monocyte Anatomy 0.000 description 10
- 206010021143 Hypoxia Diseases 0.000 description 9
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 8
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 230000003466 anti-cipated effect Effects 0.000 description 8
- 210000001772 blood platelet Anatomy 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 239000000825 pharmaceutical preparation Substances 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 102000003814 Interleukin-10 Human genes 0.000 description 7
- 108090000174 Interleukin-10 Proteins 0.000 description 7
- 102100026871 Interleukin-9 Human genes 0.000 description 7
- 102000014736 Notch Human genes 0.000 description 7
- 108010070047 Notch Receptors Proteins 0.000 description 7
- 239000004372 Polyvinyl alcohol Substances 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 210000003651 basophil Anatomy 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 7
- 210000001185 bone marrow Anatomy 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000003979 eosinophil Anatomy 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 229940118526 interleukin-9 Drugs 0.000 description 7
- 210000000440 neutrophil Anatomy 0.000 description 7
- 229920002451 polyvinyl alcohol Polymers 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 102100035716 Glycophorin-A Human genes 0.000 description 6
- 101001074244 Homo sapiens Glycophorin-A Proteins 0.000 description 6
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 102000003815 Interleukin-11 Human genes 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000009762 endothelial cell differentiation Effects 0.000 description 6
- 230000003511 endothelial effect Effects 0.000 description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 229940074383 interleukin-11 Drugs 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 102100037362 Fibronectin Human genes 0.000 description 5
- 108010067306 Fibronectins Proteins 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 108090000978 Interleukin-4 Proteins 0.000 description 5
- 102000004388 Interleukin-4 Human genes 0.000 description 5
- 102000007547 Laminin Human genes 0.000 description 5
- 230000001464 adherent effect Effects 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 210000002304 esc Anatomy 0.000 description 5
- 230000007954 hypoxia Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 229940076144 interleukin-10 Drugs 0.000 description 5
- 230000003278 mimic effect Effects 0.000 description 5
- 230000007959 normoxia Effects 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 230000009469 supplementation Effects 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 102000000704 Interleukin-7 Human genes 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000002798 bone marrow cell Anatomy 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000001332 colony forming effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 230000011132 hemopoiesis Effects 0.000 description 4
- 230000001146 hypoxic effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000007790 scraping Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 101100394749 Arabidopsis thaliana HSFB2A gene Proteins 0.000 description 3
- 101100454433 Biomphalaria glabrata BG01 gene Proteins 0.000 description 3
- 102000004266 Collagen Type IV Human genes 0.000 description 3
- 108010042086 Collagen Type IV Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102100032606 Heat shock factor protein 1 Human genes 0.000 description 3
- 101150094793 Hes3 gene Proteins 0.000 description 3
- 101150029234 Hes5 gene Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000867525 Homo sapiens Heat shock factor protein 1 Proteins 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 206010067482 No adverse event Diseases 0.000 description 3
- 101100070550 Oryza sativa subsp. japonica HSFA2C gene Proteins 0.000 description 3
- 101100016889 Rattus norvegicus Hes2 gene Proteins 0.000 description 3
- 102000004338 Transferrin Human genes 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000004700 fetal blood Anatomy 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 238000011773 genetically engineered mouse model Methods 0.000 description 3
- 238000013537 high throughput screening Methods 0.000 description 3
- 229960000890 hydrocortisone Drugs 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000003716 mesoderm Anatomy 0.000 description 3
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000013341 scale-up Methods 0.000 description 3
- 238000007423 screening assay Methods 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 239000012581 transferrin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 2
- IYOZTVGMEWJPKR-VOMCLLRMSA-N 4-[(1R)-1-aminoethyl]-N-pyridin-4-yl-1-cyclohexanecarboxamide Chemical compound C1CC([C@H](N)C)CCC1C(=O)NC1=CC=NC=C1 IYOZTVGMEWJPKR-VOMCLLRMSA-N 0.000 description 2
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 2
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 2
- 108010042634 F2A4-K-NS peptide Proteins 0.000 description 2
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 2
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 2
- 101000797623 Homo sapiens Protein AMBP Proteins 0.000 description 2
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102100020880 Kit ligand Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102100032859 Protein AMBP Human genes 0.000 description 2
- 108010039445 Stem Cell Factor Proteins 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010293 colony formation assay Methods 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000032459 dedifferentiation Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003981 ectoderm Anatomy 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 108010045676 holotransferrin Proteins 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 108010071003 insulin-related factor Proteins 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- VGEREEWJJVICBM-UHFFFAOYSA-N phloretin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000007320 rich medium Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- ZWTDXYUDJYDHJR-UHFFFAOYSA-N (E)-1-(2,4-dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-2-propen-1-one Natural products OC1=CC(O)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O ZWTDXYUDJYDHJR-UHFFFAOYSA-N 0.000 description 1
- WEEFNMFMNMASJY-UHFFFAOYSA-M 1,2-dimethoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium;chloride Chemical compound [Cl-].C1=C2OCOC2=CC2=CC=C3C4=CC=C(OC)C(OC)=C4C=[N+](C)C3=C21 WEEFNMFMNMASJY-UHFFFAOYSA-M 0.000 description 1
- LLAPDLPYIYKTGQ-UHFFFAOYSA-N 1-aminoethyl Chemical group C[CH]N LLAPDLPYIYKTGQ-UHFFFAOYSA-N 0.000 description 1
- GBOKNHVRVRMECW-UHFFFAOYSA-N 1-pyridin-4-yl-3-(2,4,6-trichlorophenyl)urea Chemical compound ClC1=CC(Cl)=CC(Cl)=C1NC(=O)NC1=CC=NC=C1 GBOKNHVRVRMECW-UHFFFAOYSA-N 0.000 description 1
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical class N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
- LLJRXVHJOJRCSM-UHFFFAOYSA-N 3-pyridin-4-yl-1H-indole Chemical group C=1NC2=CC=CC=C2C=1C1=CC=NC=C1 LLJRXVHJOJRCSM-UHFFFAOYSA-N 0.000 description 1
- NEBCAMAQXZIVRE-UHFFFAOYSA-N 5-(methoxymethyl)-4-[2,3,4-trihydroxy-6-(methoxymethyl)phenyl]benzene-1,2,3-triol Chemical compound COCC1=CC(O)=C(O)C(O)=C1C1=C(O)C(O)=C(O)C=C1COC NEBCAMAQXZIVRE-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 101001011741 Bos taurus Insulin Proteins 0.000 description 1
- 101000766308 Bos taurus Serotransferrin Proteins 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- VDRZDTXJMRRVMF-UONOGXRCSA-N D-erythro-sphingosine Natural products CCCCCCCCCC=C[C@@H](O)[C@@H](N)CO VDRZDTXJMRRVMF-UONOGXRCSA-N 0.000 description 1
- 101000994439 Danio rerio Protein jagged-1a Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 102100031983 Ephrin type-B receptor 4 Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102100035308 Fibroblast growth factor 17 Human genes 0.000 description 1
- 102100035323 Fibroblast growth factor 18 Human genes 0.000 description 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
- 102100037665 Fibroblast growth factor 9 Human genes 0.000 description 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- CMKMGFAUKPAOMG-AWEZNQCLSA-N Glycyl-H-1152 Chemical compound C[C@H]1CN(C(=O)CN)CCCN1S(=O)(=O)C1=CC=CC2=CN=CC(C)=C12 CMKMGFAUKPAOMG-AWEZNQCLSA-N 0.000 description 1
- 101000980898 Homo sapiens Cell division cycle-associated protein 4 Proteins 0.000 description 1
- 101000878124 Homo sapiens Fibroblast growth factor 17 Proteins 0.000 description 1
- 101000878128 Homo sapiens Fibroblast growth factor 18 Proteins 0.000 description 1
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 1
- 101001027380 Homo sapiens Fibroblast growth factor 9 Proteins 0.000 description 1
- 101100340751 Homo sapiens IL3 gene Proteins 0.000 description 1
- 101001054921 Homo sapiens Lymphatic vessel endothelial hyaluronic acid receptor 1 Proteins 0.000 description 1
- 101001005719 Homo sapiens Melanoma-associated antigen 3 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- KOZFSFOOLUUIGY-SOLYNIJKSA-N K-252a Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@](C(=O)OC)(O)[C@]4(C)O1 KOZFSFOOLUUIGY-SOLYNIJKSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102100026849 Lymphatic vessel endothelial hyaluronic acid receptor 1 Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 210000002361 Megakaryocyte Progenitor Cell Anatomy 0.000 description 1
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 description 1
- 108010036176 Melitten Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- YQHMWTPYORBCMF-UHFFFAOYSA-N Naringenin chalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-UHFFFAOYSA-N 0.000 description 1
- 102000001759 Notch1 Receptor Human genes 0.000 description 1
- 108010029755 Notch1 Receptor Proteins 0.000 description 1
- FNPHNLNTJNMAEE-HSZRJFAPSA-N O-octadecanoyl-L-carnitine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C FNPHNLNTJNMAEE-HSZRJFAPSA-N 0.000 description 1
- XOMRRQXKHMYMOC-UHFFFAOYSA-N O-palmitoylcarnitine Chemical compound CCCCCCCCCCCCCCCC(=O)OC(CC([O-])=O)C[N+](C)(C)C XOMRRQXKHMYMOC-UHFFFAOYSA-N 0.000 description 1
- 208000014245 Ocular vascular disease Diseases 0.000 description 1
- IIXHQGSINFQLRR-UHFFFAOYSA-N Piceatannol Natural products Oc1ccc(C=Cc2c(O)c(O)c3CCCCc3c2O)cc1O IIXHQGSINFQLRR-UHFFFAOYSA-N 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010084535 ProNectin F Proteins 0.000 description 1
- 102100032702 Protein jagged-1 Human genes 0.000 description 1
- 102100032733 Protein jagged-2 Human genes 0.000 description 1
- 101710170213 Protein jagged-2 Proteins 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- OBZJZDHRXBKKTJ-UHFFFAOYSA-N Sangivamycin Natural products C12=NC=NC(N)=C2C(C(=O)N)=CN1C1OC(CO)C(O)C1O OBZJZDHRXBKKTJ-UHFFFAOYSA-N 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 101800001530 Thymosin alpha Proteins 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 102000008790 VE-cadherin Human genes 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 108010022164 acetyl-LDL Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000004618 arterial endothelial cell Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 108010018828 cadherin 5 Proteins 0.000 description 1
- LSUTUUOITDQYNO-UHFFFAOYSA-N calphostin C Chemical compound C=12C3=C4C(CC(C)OC(=O)C=5C=CC=CC=5)=C(OC)C(O)=C(C(C=C5OC)=O)C4=C5C=1C(OC)=CC(=O)C2=C(O)C(OC)=C3CC(C)OC(=O)OC1=CC=C(O)C=C1 LSUTUUOITDQYNO-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 108010015046 cell aggregation factors Proteins 0.000 description 1
- 238000003320 cell separation method Methods 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- JKNIRLKHOOMGOJ-UHFFFAOYSA-N cladochrome D Natural products COC1=C(CC(C)OC(=O)Oc2ccc(O)cc2)c3c4C(=C(OC)C(=O)c5c(O)cc(OC)c(c45)c6c(OC)cc(O)c(C1=O)c36)CC(C)OC(=O)c7ccc(O)cc7 JKNIRLKHOOMGOJ-UHFFFAOYSA-N 0.000 description 1
- SRJYZPCBWDVSGO-UHFFFAOYSA-N cladochrome E Natural products COC1=CC(O)=C(C(C(OC)=C(CC(C)OC(=O)OC=2C=CC(O)=CC=2)C2=3)=O)C2=C1C1=C(OC)C=C(O)C(C(C=2OC)=O)=C1C=3C=2CC(C)OC(=O)C1=CC=CC=C1 SRJYZPCBWDVSGO-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000000093 cytochemical effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000003315 endocardial cell Anatomy 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000044493 human CDCA4 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 1
- BTXNYTINYBABQR-UHFFFAOYSA-N hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 description 1
- 229940005608 hypericin Drugs 0.000 description 1
- PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical class N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000012760 immunocytochemical staining Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000006517 limb development Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005073 lymphatic endothelial cell Anatomy 0.000 description 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 239000012577 media supplement Substances 0.000 description 1
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000008271 nervous system development Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- CDRPUGZCRXZLFL-OWOJBTEDSA-N piceatannol Chemical compound OC1=CC(O)=CC(\C=C\C=2C=C(O)C(O)=CC=2)=C1 CDRPUGZCRXZLFL-OWOJBTEDSA-N 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- OBZJZDHRXBKKTJ-JTFADIMSSA-N sangivamycin Chemical compound C12=NC=NC(N)=C2C(C(=O)N)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OBZJZDHRXBKKTJ-JTFADIMSSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000012090 serum-supplement Substances 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000005309 stochastic process Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229960003454 tamoxifen citrate Drugs 0.000 description 1
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15630409P | 2009-02-27 | 2009-02-27 | |
| US61/156,304 | 2009-02-27 | ||
| PCT/US2010/025776 WO2010099539A1 (en) | 2009-02-27 | 2010-03-01 | Differentiation of pluripotent cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015158092A Division JP2015192681A (ja) | 2009-02-27 | 2015-08-10 | 多能性細胞の分化 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012519005A JP2012519005A (ja) | 2012-08-23 |
| JP2012519005A5 true JP2012519005A5 (enExample) | 2013-04-18 |
| JP5816100B2 JP5816100B2 (ja) | 2015-11-18 |
Family
ID=42097524
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011552223A Active JP5816100B2 (ja) | 2009-02-27 | 2010-03-01 | 多能性細胞の分化 |
| JP2015158092A Pending JP2015192681A (ja) | 2009-02-27 | 2015-08-10 | 多能性細胞の分化 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015158092A Pending JP2015192681A (ja) | 2009-02-27 | 2015-08-10 | 多能性細胞の分化 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8372642B2 (enExample) |
| EP (1) | EP2401364B1 (enExample) |
| JP (2) | JP5816100B2 (enExample) |
| KR (1) | KR101720961B1 (enExample) |
| CN (1) | CN102388130B (enExample) |
| AU (1) | AU2010217739B2 (enExample) |
| CA (1) | CA2753679C (enExample) |
| IL (1) | IL214818A (enExample) |
| WO (1) | WO2010099539A1 (enExample) |
Families Citing this family (138)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102510368B1 (ko) | 2006-04-14 | 2023-03-14 | 아스텔라스 인스티튜트 포 리제너러티브 메디슨 | 혈관 콜로니 형성 세포 |
| US8741644B2 (en) | 2009-09-08 | 2014-06-03 | Kyoto University | Method for producing mast cells from pluripotent stem cells |
| CA3174901A1 (en) | 2009-11-12 | 2011-05-19 | Technion Research & Development Foundation Ltd. | Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state |
| WO2011068792A2 (en) * | 2009-12-01 | 2011-06-09 | The Regents Of The University Of California | Compositions and methods for making and using bone marrow mesenchymal stem cells and erythroid progenitor cells |
| US8822218B2 (en) * | 2009-12-04 | 2014-09-02 | Stem Cell & Regenerative Medicine International, Inc. | Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts |
| US9428735B2 (en) | 2010-02-25 | 2016-08-30 | The Johns Hopkins University | Smooth muscle-like cells (SMLCs) dervided from human pluripotent stem cells |
| WO2011159684A2 (en) | 2010-06-15 | 2011-12-22 | Cellular Dynamics International, Inc. | Generation of induced pluripotent stem cells from small volumes of peripheral blood |
| US8765470B2 (en) | 2010-08-04 | 2014-07-01 | Cellular Dynamics International, Inc. | Reprogramming immortalized B-cells to induced pluripotent stem cells |
| CN102985531B (zh) | 2010-09-10 | 2019-04-23 | 国立大学法人东京大学 | 涉及由多能干细胞向血细胞分化的培养方法 |
| WO2012103098A2 (en) * | 2011-01-24 | 2012-08-02 | Immunepath, Inc. | Compositions and methods for treating hematological cytopenias |
| JP6148429B2 (ja) * | 2011-01-31 | 2017-06-14 | 協和発酵バイオ株式会社 | ヒト多能性幹細胞の培養方法 |
| JP6005666B2 (ja) * | 2011-02-08 | 2016-10-12 | セルラー ダイナミクス インターナショナル， インコーポレイテッド | プログラミングによる造血前駆細胞の生産 |
| CN102161980B (zh) * | 2011-02-12 | 2013-07-31 | 浙江大学 | 用人间充质干细胞为滋养层培养诱导多能干细胞的方法 |
| US9499789B2 (en) | 2011-02-23 | 2016-11-22 | Kyoto University | Method for producing dendritic cells from pluripotent stem cells |
| GB201103600D0 (en) | 2011-03-01 | 2011-04-13 | Isis Innovation | Dendritic cells |
| US9169309B2 (en) * | 2011-03-01 | 2015-10-27 | Humanzyme Inc. | Thermostable variants of fibroblast growth factors |
| EP2694644B1 (en) * | 2011-03-30 | 2018-01-24 | Cellular Dynamics International, Inc. | Priming of pluripotent stem cells for neural differentiation |
| WO2012168167A1 (en) * | 2011-06-09 | 2012-12-13 | F. Hoffmann-La Roche Ag | Method for differentiation of pluripotent stem cells into vascular bed cells |
| MX348188B (es) * | 2011-09-29 | 2017-06-01 | Cellsnap Llc | Composiciones y metodos para pruebas de toxigenicidad. |
| EP2765187B1 (en) * | 2011-10-03 | 2018-08-08 | Nissan Chemical Industries, Ltd. | Method for producing megakaryocytes and/or platelets from pluripotent stem cells |
| CN110241083A (zh) * | 2011-11-21 | 2019-09-17 | 大学健康网络 | 造血祖细胞群体和富集其干细胞的方法 |
| LT2785359T (lt) | 2011-11-30 | 2018-11-12 | Astellas Institute For Regenerative Medicine | Mezenchiminės stromos ląstelės ir su jomis susiję naudojimo būdai |
| US8961956B2 (en) | 2011-11-30 | 2015-02-24 | Ocata Therapeutics, Inc. | Mesenchymal stromal cells and uses related thereto |
| CA2857295C (en) * | 2011-12-01 | 2021-06-29 | New York Stem Cell Foundation | Automated system for producing induced pluripotent stem cells or differentiated cells |
| US10428309B2 (en) | 2011-12-01 | 2019-10-01 | New York Stem Cell Foundation, Inc. | Systems and methods for producing stem cells and differentiated cells |
| EP2820123B1 (en) * | 2012-02-29 | 2017-10-11 | The Johns Hopkins University | Method for guiding the derivation of endothelial cells from human pluripotent stem cells employing two-dimensional, feeder-free differentiation |
| US9260696B2 (en) | 2012-04-24 | 2016-02-16 | Dan S. Kaufman | Method for developing natural killer cells from stem cells |
| GB201210857D0 (en) | 2012-06-19 | 2012-08-01 | Cambridge Entpr Ltd | Transcription factor mediated programming towards megakaryocytes |
| CA2876499C (en) | 2012-07-12 | 2021-10-26 | Imstem Biotechnology, Inc. | Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof |
| US10286014B2 (en) * | 2012-09-28 | 2019-05-14 | Foundation For Biomedical Research And Innovation At Kobe | Method for in vitro proliferation of cell population containing cells suitable for treatment of ischemic disease |
| CA2885294A1 (en) | 2012-11-21 | 2014-05-30 | Merz Pharma Gmbh & Co. Kgaa | Means and methods for determination of botulinum neurotoxin biological activity |
| US10426799B2 (en) | 2012-12-21 | 2019-10-01 | Astellas Institute For Regenerative Medicine | Methods for production of platelets from pluripotent stem cells and compositions thereof |
| CA2905786C (en) | 2013-03-13 | 2022-01-25 | Wisconsin Alumni Research Foundation | Methods and materials for hematoendothelial differentiation of human pluripotent stem cells under defined conditions |
| EP2970902B1 (en) * | 2013-03-15 | 2019-11-20 | The Johns Hopkins University | Self-organized vascular networks from human pluripotent stem cells in a synthetic matrix |
| US10731132B2 (en) | 2013-03-15 | 2020-08-04 | Amniotics Ab | Methods and apparatuses for umbilical cord blood collection and isolation of cells |
| US9506037B2 (en) | 2013-03-15 | 2016-11-29 | The Johns Hopkins University | Self-organized vascular networks from human pluripotent stem cells in a synthetic matrix |
| US9994825B2 (en) | 2013-03-15 | 2018-06-12 | The Johns Hopkins University | Self-organized vascular networks from human pluripotent stem cells in a synthetic matrix |
| JP6429280B2 (ja) * | 2013-05-14 | 2018-11-28 | 国立大学法人京都大学 | 効率的な心筋細胞の誘導方法 |
| JP5511039B1 (ja) * | 2013-05-22 | 2014-06-04 | 国立大学法人九州大学 | Ｎｋ細胞の調製方法 |
| WO2014189144A1 (ja) * | 2013-05-23 | 2014-11-27 | 国立大学法人京都大学 | 骨髄異形成症候群等の治療／予防薬のスクリーニング方法 |
| WO2014200340A1 (en) * | 2013-06-10 | 2014-12-18 | Academisch Ziekenhuis Leiden | Differentiation and expansion of endothelial cells from pluripotent stem cells and the in vitro formation of vasculature like structures |
| SG11201510685UA (en) | 2013-06-28 | 2016-01-28 | Merz Pharma Gmbh & Co Kgaa | Means and methods for the determination of the biological activity of neurotoxin polypeptides in cells |
| EP3052615B1 (en) | 2013-10-01 | 2021-12-29 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Human ipsc-derived vascular-related and hematopoetic cells for therapies and toxicology/drug screenings |
| WO2015119642A1 (en) * | 2014-02-10 | 2015-08-13 | The Johns Hopkins University | Low oxygen tension enhances endothelial fate of human pluripotent stem cells |
| HK1226481B (zh) | 2014-02-19 | 2017-09-29 | 莫茨药物股份两合公司 | 在体外试验系统中用於使细胞对肉毒神经毒素的敏感性标准化和增加的神经节苷脂 |
| JP6933898B2 (ja) | 2014-04-24 | 2021-09-08 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | 養子細胞治療製品を製造するための誘導多能性幹細胞の適用 |
| CN103937743B (zh) * | 2014-04-27 | 2017-12-01 | 浙江大学 | 一种利用三维诱导系统获得造血干细胞的方法 |
| MX382747B (es) | 2014-08-04 | 2025-03-11 | Nuevolution As | Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas oncológicas y autoinmunitarias. |
| JP6772138B2 (ja) | 2014-12-19 | 2020-10-21 | メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー | 細胞内のＢｏＮＴ／Ｅの生物学的活性を決定するための手段及び方法 |
| US10724003B2 (en) | 2015-01-16 | 2020-07-28 | Agency For Science, Technology And Research | Method of differentiating human pluripotent stem cells into primitive macrophages |
| US9828634B2 (en) | 2015-01-22 | 2017-11-28 | Regenerative Medical Solutions, Inc. | Markers for differentiation of stem cells into differentiated cell populations |
| AU2016211671B2 (en) * | 2015-01-26 | 2022-05-26 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| TWI704156B (zh) | 2015-03-04 | 2020-09-11 | 德商曼茲法瑪股份有限公司 | 用於增進肉毒桿菌神經毒素進入細胞之特定攝取的方法 |
| EP3298131B1 (en) * | 2015-05-20 | 2023-04-26 | The Regents of The University of California | Method for generating human dendritic cells for immunotherapy |
| EP4026563B1 (en) * | 2015-06-18 | 2025-10-29 | Yeda Research and Development Co. Ltd | Conditioning protocols and use of same for tissue regeneration |
| JP6884354B2 (ja) | 2015-09-08 | 2021-06-09 | 大日本住友製薬株式会社 | 網膜組織の製造方法 |
| JP7061961B2 (ja) * | 2015-10-20 | 2022-05-02 | フジフィルム セルラー ダイナミクス，インコーポレイテッド | 多能性幹細胞の免疫細胞への分化を誘導する方法 |
| CA3003145C (en) | 2015-10-30 | 2025-11-18 | The Regents Of The University Of California | METHODS FOR GENERATION OF T LYMPHOCYTES FROM STEM CELLS AND IMMUNOTHERAPY METHODS USING SAID T LYMPHOCYTES |
| SG11201803145RA (en) | 2015-11-04 | 2018-05-30 | Fate Therapeutics Inc | Methods and compositions for inducing hematopoietic cell differentiation |
| CN108368520B (zh) | 2015-11-04 | 2023-01-17 | 菲特治疗公司 | 多能细胞的基因组工程改造 |
| CN105296428A (zh) * | 2015-12-03 | 2016-02-03 | 广州医科大学附属第三医院 | 一种提高诱导多能干细胞的体外分化造血效率的方法 |
| US20190002834A1 (en) * | 2015-12-29 | 2019-01-03 | Kuraray Co., Ltd. | Method for preparing population of stem cell spheroids |
| GB201601503D0 (en) | 2016-01-27 | 2016-03-09 | Isis Innovation | Dendritic cells |
| CN111334463B (zh) | 2016-05-18 | 2024-02-20 | 学校法人庆应义塾 | 类器官培养用细胞培养基、培养方法及类器官 |
| WO2018021566A1 (ja) * | 2016-07-29 | 2018-02-01 | ダイキン工業株式会社 | 分化細胞の製造方法、及びその製造方法のために使用する培養バッグ |
| JP6963555B2 (ja) * | 2016-09-02 | 2021-11-10 | タカラバイオ株式会社 | 多能性幹細胞からミクログリアを得る方法 |
| EP3510145A4 (en) | 2016-09-06 | 2020-03-25 | The Children's Medical Center Corporation | IMMUNCELLS FROM INDUCED PLURIPOTENT STEM CELLS |
| CN110023491B (zh) * | 2016-10-05 | 2024-03-08 | 富士胶片细胞动力公司 | 多能干细胞定向分化为hla纯合免疫细胞的方法 |
| US10961505B2 (en) | 2016-10-05 | 2021-03-30 | FUJIFILM Cellular Dynamics, Inc. | Generating mature lineages from induced pluripotent stem cells with MECP2 disruption |
| CN106479968A (zh) * | 2016-10-11 | 2017-03-08 | 海南博鳌龄迈迪精准医学研究院有限公司 | 脐带间充质干细胞的培养方法 |
| WO2018073615A1 (en) | 2016-10-21 | 2018-04-26 | Longboat Explorers Ab | Methods and compositions for generating hematopoietic cells |
| CN106754684A (zh) * | 2017-01-05 | 2017-05-31 | 厚朴生物科技（苏州）有限公司 | 一种睾丸间质干细胞分离培养分化方法 |
| WO2018139600A1 (ja) | 2017-01-27 | 2018-08-02 | 株式会社カネカ | 内胚葉系細胞集団、及び多能性細胞から三胚葉のいずれかの細胞集団を製造する方法 |
| CN110520167B (zh) * | 2017-02-03 | 2023-03-24 | 康奈尔大学 | 稳定的三维血管和形成其的方法 |
| WO2018172420A1 (en) * | 2017-03-21 | 2018-09-27 | Etablissement Francais Du Sang | Methods of improving hematopoietic grafts |
| JP7181219B2 (ja) | 2017-04-18 | 2022-11-30 | フジフィルム セルラー ダイナミクス，インコーポレイテッド | 抗原特異的免疫エフェクター細胞 |
| EP3399027A1 (en) | 2017-05-04 | 2018-11-07 | Medizinische Hochschule Hannover | Stem-cell derived myeloid cells, generation and use thereof |
| CN107083367B (zh) * | 2017-07-03 | 2020-07-14 | 广州润虹医药科技股份有限公司 | 培养基及其用途与由尿液细胞制备间充质干细胞的方法 |
| CN110770335A (zh) * | 2017-12-11 | 2020-02-07 | 韩国疾病预防控制中心 | 使用多能干细胞的免疫细胞的分化 |
| US11365390B2 (en) | 2017-12-19 | 2022-06-21 | Xcell Biosciences, Inc. | Methods of modulating cell phenotype by way of regulating the gaseous environment |
| CN108048390B (zh) * | 2017-12-21 | 2021-04-27 | 清华大学 | 一种制备血管内皮细胞的方法及其专用试剂盒 |
| CN108588024B (zh) * | 2017-12-29 | 2020-04-21 | 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） | 诱导多能干细胞分化成造血干细胞的培养基及方法 |
| CN111836886A (zh) * | 2018-01-05 | 2020-10-27 | 血小板生源说股份有限公司 | 用于产生巨核细胞的组合物和方法 |
| SG11202007221QA (en) | 2018-02-01 | 2020-08-28 | Nkmax Co Ltd | Method of producing natural killer cells and composition for treating cancer |
| FR3079239A1 (fr) * | 2018-03-23 | 2019-09-27 | Centre National De La Recherche Scientifique | Nouvelle methode d’obtention de cellules t a partir de cellules souches pluripotentes, et leurs utilisations |
| US12403161B2 (en) | 2018-06-29 | 2025-09-02 | Stellular Bio, Inc. | Compositions for drug delivery and methods of use thereof |
| KR20210061397A (ko) | 2018-09-19 | 2021-05-27 | 후지필름 셀룰러 다이내믹스, 인코포레이티드 | 키메라 항원 수용체-변형된 면역 세포의 활성화 및 확장을 위한 단백질 l |
| CN109266618B (zh) * | 2018-10-18 | 2021-04-23 | 赛元生物科技(杭州)有限公司 | 能够靶向肿瘤细胞的巨噬细胞及其制备方法 |
| BR112021007748A2 (pt) * | 2018-10-24 | 2021-07-27 | Hebecell Corporation | métodos e sistemas para fabricar células de linhagem hematopoiética |
| KR102111441B1 (ko) * | 2018-11-12 | 2020-05-15 | 대한민국 | 전분화능 줄기세포 유래 대식세포를 기반으로 하는 감염질환 치료용 약물 스크리닝 방법 |
| TWI843782B (zh) * | 2018-12-20 | 2024-06-01 | 日商住友化學股份有限公司 | 含有胚胎型紅血球母細胞的細胞集團的製造方法及化合物試驗法 |
| JP7634938B2 (ja) * | 2019-02-21 | 2025-02-25 | ピービーエス バイオテック インコーポレイテッド | バイオリアクターにおける治療細胞の膨張および分化のためのシステムおよび方法 |
| CN111206017B (zh) * | 2019-04-30 | 2022-02-18 | 浙江大学 | 一种干细胞无血清培养基及其应用 |
| KR20220032561A (ko) * | 2019-06-14 | 2022-03-15 | 후지필름 셀룰러 다이내믹스, 인코포레이티드 | 하전된 표면을 사용하여 유도 만능 줄기 세포로부터 다중 계통을 생산하는 방법 |
| WO2020256628A1 (en) | 2019-06-20 | 2020-12-24 | Amniotics Ab | An apparatus for filtering amniotic fluid |
| EP4045068A1 (en) | 2019-10-18 | 2022-08-24 | Amniotics AB | Use of term amniotic fluid cells for the treatment of acute and chronic respiratory diseases |
| JP7479466B2 (ja) | 2019-11-13 | 2024-05-08 | カリス バイオ インコーポレイテッド | 血管内皮細胞純粋分離方法、血管内皮細胞特性維持培地及びそれを含む培養方法 |
| CN110938584B (zh) * | 2019-11-25 | 2021-12-03 | 广州赛莱拉干细胞科技股份有限公司 | 一种人胚胎干细胞向内皮细胞诱导分化的方法 |
| CA3160522A1 (en) | 2019-12-20 | 2021-06-24 | Sanne Schroder Glad | Compounds active towards nuclear receptors |
| UY38994A (es) | 2019-12-20 | 2021-07-30 | Nuevolution As | Compuestos activos frente a receptores nucleares |
| CN115135754A (zh) * | 2020-02-28 | 2022-09-30 | 普渡研究基金会 | 在限定条件下从人多能干细胞生成主动脉-性腺-中肾样造血细胞 |
| US12220445B2 (en) | 2020-03-09 | 2025-02-11 | Amprion, Inc. | Inert matrices for qualitative and semi-quantitative seed amplification assays |
| CN111440760B (zh) * | 2020-03-09 | 2022-09-23 | 浙江大学 | 一种人多能干细胞高效分化得到内皮祖细胞的方法 |
| US11547726B2 (en) | 2020-03-26 | 2023-01-10 | Honed Life Sciences, Llc | Enhancement of production of NK cells from stem cells |
| CA3174176A1 (en) | 2020-03-31 | 2021-10-07 | Sanne Schroder Glad | Compounds active towards nuclear receptors |
| AU2021245397A1 (en) | 2020-03-31 | 2022-10-20 | Nuevolution A/S | Compounds active towards nuclear receptors |
| US20230257705A1 (en) | 2020-06-17 | 2023-08-17 | Kyoto University | Chimeric antigen receptor-expressing immunocompetent cells |
| EP4189068A4 (en) * | 2020-07-27 | 2024-08-28 | Stemcell Technologies Canada Inc. | SYSTEMS AND METHODS FOR DIFFERENTIATION OF HEMATOPOETIC CELLS |
| CN111808812B (zh) * | 2020-08-31 | 2020-12-15 | 首都医科大学附属北京友谊医院 | 一种用于多能干细胞向造血干细胞分化的材料和方法 |
| US12435308B2 (en) | 2020-11-06 | 2025-10-07 | Amniotics Ab | Immunomodulation by amniotic fluid mesenchymal stem cells |
| EP4251741A1 (en) | 2020-11-30 | 2023-10-04 | CRISPR Therapeutics AG | Gene-edited natural killer cells |
| KR20230118887A (ko) | 2020-12-03 | 2023-08-14 | 센츄리 쎄라퓨틱스 인코포레이티드 | 유전자 조작 세포 및 이의 용도 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| CN112608895B (zh) * | 2020-12-18 | 2024-02-27 | 深圳市济因生物科技有限公司 | 一种人多能干细胞分化的自然杀伤细胞及其制备方法与应用 |
| US11473060B2 (en) | 2020-12-30 | 2022-10-18 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into NK cells |
| EP4320224A1 (en) | 2021-04-07 | 2024-02-14 | Century Therapeutics, Inc. | Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells |
| WO2022216514A1 (en) | 2021-04-07 | 2022-10-13 | Century Therapeutics, Inc. | Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells |
| JP2024513454A (ja) | 2021-04-07 | 2024-03-25 | センチュリー セラピューティクス，インコーポレイテッド | キメラ抗原受容体細胞のための人工細胞死／リポーター系ポリペプチドの組合せおよびその使用 |
| AU2022253891A1 (en) | 2021-04-07 | 2023-08-24 | Century Therapeutics, Inc. | Gene transfer vectors and methods of engineering cells |
| US20240191186A1 (en) | 2021-05-05 | 2024-06-13 | FUJIFILM Cellular Dynamics, Inc. | Methods and compositions for ipsc-derived microglia |
| CA3231278A1 (en) | 2021-09-10 | 2023-03-16 | Deepika Rajesh | Compositions of induced pluripotent stem cell-derived cells and methods of use thereof |
| KR20240067087A (ko) * | 2021-09-13 | 2024-05-16 | 암프리온, 인코퍼레이티드 | 정성적 및 반정량적 시드 증폭 검정을 위한 불활성 매트릭스 |
| WO2023110045A1 (en) | 2021-12-15 | 2023-06-22 | Y-Mabs Therapeutics, Inc. | Scfv and antibodies with reduced multimerisation |
| WO2023129937A1 (en) | 2021-12-29 | 2023-07-06 | Century Therapeutics, Inc. | Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof |
| WO2023164440A1 (en) | 2022-02-22 | 2023-08-31 | Juno Therapeutics, Inc. | Proteinase 3 (pr3) chimeric autoantibody receptor t cells and related methods and uses |
| US20250345425A1 (en) | 2022-05-04 | 2025-11-13 | Century Therapeutics, Inc. | Cells engineered with an hla-e and hla-g transgene |
| JP2025522360A (ja) | 2022-06-08 | 2025-07-15 | センチュリー セラピューティクス，インコーポレイテッド | Ｃｄ１６変異体およびｎｋｇ２ｄを発現する遺伝子操作した細胞ならびにその使用 |
| US20250090582A1 (en) | 2022-06-08 | 2025-03-20 | Century Therapeutics, Inc. | Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof |
| WO2023240169A1 (en) | 2022-06-08 | 2023-12-14 | Century Therapeutics, Inc. | Immunoeffector cells derived from induced pluripotent stem cells genetically engineered with membrane bound il12 and uses thereof |
| WO2024102838A1 (en) | 2022-11-09 | 2024-05-16 | Century Therapeutics, Inc. | Engineered interleukin-7 receptors and uses thereof |
| WO2024103017A2 (en) | 2022-11-10 | 2024-05-16 | Century Therapeutics, Inc. | Genetically engineered cells having anti-nectin4 chimeric antigen receptors, and uses thereof |
| US20240269189A1 (en) | 2022-12-19 | 2024-08-15 | FUJIFILM Holdings America Corporation | Extracellular vesicle-enriched secretome composition derived from induced pluripotent stem cell derived-microglia and methods of use thereof |
| EP4665846A2 (en) * | 2023-02-16 | 2025-12-24 | Syntax Bio, Inc. | Systems for cell programming towards hematopoietic lineage and methods thereof |
| CN116426472A (zh) * | 2023-06-08 | 2023-07-14 | 呈诺再生医学科技(北京)有限公司 | 一种促进造血干细胞或造血祖细胞分化为红细胞的诱导分化体系及其应用 |
| WO2025101938A2 (en) | 2023-11-10 | 2025-05-15 | Century Therapeutics, Inc. | Genetically engineered cells having multi-transmembrane domain chimeric antigen receptors utilizing g protein-coupled receptor scaffolds, and uses thereof |
| WO2025106626A1 (en) | 2023-11-15 | 2025-05-22 | Century Therapeutics, Inc. | Genetically engineered cells expressing c-x-c chemokine receptor type 4, and uses thereof |
| WO2025207795A1 (en) | 2024-03-26 | 2025-10-02 | Juno Therapeutics, Inc. | Genetically engineered cells having anti-cd33 / anti-cd123 chimeric antigen receptors, and uses thereof |
| WO2025207798A1 (en) | 2024-03-26 | 2025-10-02 | Century Therapeutics, Inc. | Genetically engineered cells having anti-cd123 chimeric antigen receptors, and uses thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0187371B1 (en) | 1984-12-27 | 1991-06-19 | Asahi Kasei Kogyo Kabushiki Kaisha | Substituted isoquinolinesulfonyl compounds |
| CA2259012C (en) | 1996-07-19 | 2008-05-13 | Gunnar Aberg | S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders |
| WO1998030679A1 (en) | 1997-01-10 | 1998-07-16 | Life Technologies, Inc. | Embryonic stem cell serum replacement |
| EP1163910B1 (en) | 1999-03-25 | 2007-09-26 | Mitsubishi Pharma Corporation | Rho kinase inhibitors for the prevention or treatment of interstitial pneumonia and pulmonary fibrosis |
| WO2000078351A1 (en) | 1999-06-18 | 2000-12-28 | Mitsubishi Pharma Corporation | Osteogenesis promoters |
| US7838289B2 (en) * | 2001-02-14 | 2010-11-23 | Abt Holding Company | Assay utilizing multipotent adult stem cells |
| IL162130A0 (en) * | 2001-12-07 | 2005-11-20 | Robarts Res Inst | Hematopoietic cells from human embryonic stem cells |
| DE60236016D1 (de) * | 2001-12-21 | 2010-05-27 | Mount Sinai Hospital Corp | Zelluläre zusammensetzungen und verfahren zur deren bereitung und verwendung |
| JP4423043B2 (ja) * | 2002-01-23 | 2010-03-03 | バイエル ファーマセチカル コーポレーション | Ｒｈｏ−キナーゼ阻害剤 |
| US6664266B2 (en) * | 2002-03-14 | 2003-12-16 | Children's Medical Center Corporation | Axon regeneration with PKC inhibitiors |
| GB0206860D0 (en) | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
| WO2003089457A2 (en) * | 2002-04-22 | 2003-10-30 | The Board Of Trustees Of The Leland Stanford Junior University | Peptide inhibitors of protein kinase c ϝ for pain management |
| US7723106B2 (en) * | 2004-07-29 | 2010-05-25 | Food Industry Research & Development Institute | Stroma-free, serum-free, and chemically defined medium and method for ex vivo mononuclear cell expansion using the same |
| WO2005086902A2 (en) | 2004-03-08 | 2005-09-22 | Wyeth | Ion channel modulators |
| US7452718B2 (en) * | 2004-03-26 | 2008-11-18 | Geron Corporation | Direct differentiation method for making cardiomyocytes from human embryonic stem cells |
| AU2005282510B2 (en) * | 2004-09-08 | 2010-12-02 | Wisconsin Alumni Research Foundation | Medium and culture of embryonic stem cells |
| NZ554866A (en) | 2004-11-01 | 2010-12-24 | Wisconsin Alumni Res Found | Platelets from stem cells |
| US20070077654A1 (en) | 2004-11-01 | 2007-04-05 | Thomson James A | Platelets from stem cells |
| JP4964121B2 (ja) | 2005-02-23 | 2012-06-27 | 財団法人先端医療振興財団 | 血管内皮前駆細胞の生体外増幅方法 |
| US20070128669A1 (en) * | 2005-11-28 | 2007-06-07 | Institute For Chemical Genomics | Serum-free expansion of cells in culture |
| JP2008099662A (ja) * | 2006-09-22 | 2008-05-01 | Institute Of Physical & Chemical Research | 幹細胞の培養方法 |
| US20110151554A1 (en) * | 2006-11-09 | 2011-06-23 | Akira Yuo | Method for culturing and subculturing primate embryonic stem cell, as well as method for inducing differentiation thereof |
| JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
| GB2470689A (en) * | 2008-03-27 | 2010-12-01 | Geron Corp | Differentiation of primate pluripotent stem cells to hematopoietic lineage cells |
| JP5632831B2 (ja) | 2008-05-02 | 2014-11-26 | セルラー ダイナミクス インターナショナル， インコーポレイテッド | 幹細胞からの肥満細胞の生産のための方法 |
| US20110263016A1 (en) * | 2008-09-25 | 2011-10-27 | Rancourt Derrick E | Expansion of Embryonic Stem Cells |
-
2010
- 2010-03-01 CA CA2753679A patent/CA2753679C/en active Active
- 2010-03-01 AU AU2010217739A patent/AU2010217739B2/en active Active
- 2010-03-01 KR KR1020117022315A patent/KR101720961B1/ko active Active
- 2010-03-01 US US12/715,136 patent/US8372642B2/en active Active
- 2010-03-01 WO PCT/US2010/025776 patent/WO2010099539A1/en not_active Ceased
- 2010-03-01 EP EP20100707179 patent/EP2401364B1/en active Active
- 2010-03-01 JP JP2011552223A patent/JP5816100B2/ja active Active
- 2010-03-01 CN CN201080016131.9A patent/CN102388130B/zh active Active
-
2011
- 2011-08-24 IL IL214818A patent/IL214818A/en active IP Right Grant
-
2013
- 2013-02-01 US US13/757,263 patent/US10100282B2/en active Active
-
2015
- 2015-08-10 JP JP2015158092A patent/JP2015192681A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5816100B2 (ja) | 多能性細胞の分化 | |
| JP2012519005A5 (enExample) | ||
| AU2020264375B2 (en) | Method for developing natural killer cells from stem cells | |
| JP6189581B2 (ja) | 幹細胞の分化のための方法および組成物 | |
| CN117264888A (zh) | 一种制备造血干细胞和祖细胞的方法 | |
| HK40017506A (en) | Method for developing natural killer cells from stem cells | |
| HK1218927A1 (en) | Methods and materials for hematoendothelial differentiation of human pluripotent stem cells under defined conditions |